Thank you and thank you all for joining our call.
We announced the financial results for our third quarter ended September 30, 2018 a few minutes ago.
I will to include begin, our everyone I today comments some before would remind like that But forward-looking statements.
a today’s in involve are with statements number and risks These uncertainties, the outlined SEC. in reports press our and release and filings of which
call, may measures. this will actual statements. results in forward-looking to materially differ Our also those refer from the On we financial non-GAAP
with to and will months more measures the follow open we reconciling Puma results press today, find a with non-GAAP comments would our financial our our press on I X financial signing agreement the items quarter a X to Investors with the second GAAP Vicky me the West for Biotechnology release October, table today’s the up Vicky questions. Hahne, of clinical www.celcuity.com I September the few website, which in first can release then XXXX earnings also CFO. then trial a am and You to our in call Center. Well, make on XX, some in was pleased ended and on measures have and for section. Cancer we will under is announced included available line Today’s on release. like details the third
interest initially to Our us. aren’t roadmap cancer the on the therapies to identified subtypes identifying we clinical of new the patient approach is new populations and for targeted
long-term and Puma pharmaceutical building negotiating Cancer of research with leaders. lengthy imagine companies, marks and and and discussing with a pharmaceutical opinion would organizations with in partnerships research important cancer milestone Center The So arrangements you leading West arrangement organizations our an process. major as key strategy and companies these is other complex
West to Cancer we So and this to trial. with now working implement Center clinical very excited Puma begin are
efficacy HERX of triple-negative signaling received stage the X early will treatment hyperactive the Puma’s our neratinib, by identified cancer or as cell its have HSF positive for the Nerlynx of extended also Nerlynx, early trial. will HERX as CELx FACT tumors transduction FACT X mid-XXXX. trial inhibitor, for in to this adjuvant approval live who breast analysis known We X cancer evaluate stage refer in for breast functional patients as signaling trial pan-HER Test.
Our independent studies Nerlynx tumor that is negative and evaluating that hyperactive activity Nerlynx inhibitor signaling HERX preclinical HERX effective signaling HERX of HERX very samples and activity. show well breast as HERX-driven a as have signaling cancer
planning XX now excited are study is patients. a up enroll in trial to We to center. to Nerlynx The clinical
review rates, We in to results received. final expects once expect based to of results interim XX the begin XXXX and patient in after months West XX is to institutional Celcuity enrolled obtain first enrollment patient XX XX estimate Center’s enrollment And board months. on to within approval Cancer is
CELx cancer function trials clinical CELx anti-HERX and HSF Perjeta first clinical to have will the in efficacy efficacy This in we to process Foundation arrangement, breast in NSABP are drugs, cancer evaluate is test. FACT selected by in in refer also of combination FACT designed trial stage patients we progress. Genentech’s trial means by the HERX Genentech test. of fielding Herceptin the our to negative HERX evaluate early signaling of patients trial, Our which with two we negative and is selected clinical two the collaboration continuing breast HERX X This HERX as to with X trial drugs our
and Center, the West Foundation the well-respected research clinical Cancer the are collaborators, cancer amongst most country. organizations in NSABP Our the
for to lead breast patients. that collaborations hopeful trial are better cancer these clinical options We eventually can treatment
cancer been EGFR X to they samples in fielding patients. inhibitor, are This and have Nerlynx; inhibitor, Genentech’s metastatic is pan-HER Herceptin; patient Foundation NSABP study the and evaluating Squibb’s HERX and used colorectal after be our antibody, Technology’s CELx will enrolled Puma test addition, trial trial. a Bristol-Myers the evaluate In Phase Erbitux, progressing Puma in
the We most characteristics, to expect trial our correlative response. drug CELx test will about is insight after provide patient critical the completed
trial, CELx different breast signaling our furthering During capability continued advancing we To tests two technology efforts signaling our microenvironment to signal these and of dysfunction. to also projects, cancer support the cell develop for our we new are types. our function assess and types
the opportunity hope offers through these efficacy Our or work We and efforts selected expand additional patient the biomarker co-activated signaling pharmaceutical c-Met therapies hyperactive continued. first, evaluate to in cancer populations. using the approvals breast help we have tumors. FDA companies collaborations to tumors and these signaling hope a therapeutics are our CELx patients molecular who companies targeted either therapies of the patient successful, with and patients, additional targeted and and test CELx population these test hyperactive efficacy the to subgroups therapeutics treat beyond to HERX patient to HERX to new gain targeted of We to initiate their identify if with evaluate believe
leading CELx addition, therapeutics we efficacy us identify in test study targeted to In identifies. continue the patient to researchers the with collaborating interested in of cancer populations our
review are excited made the to of our about we progress now very like during turn it to we would over I Vicky financial overall, the So quarter. to results.
